Ventyx Biosciences' (VTYX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Ventyx Biosciences' stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, despite a recent upgrade from Wall Street Zen to a "hold" rating.
• The company reported a quarterly earnings per share of ($0.38), exceeding expectations by $0.07, with analysts predicting an annual EPS of -2.09.
• Hedge funds own 97.88% of Ventyx Biosciences' stock, with some institutions notably increasing their stakes in the company during the second quarter.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Ventyx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $7.50.

Ventyx Biosciences Stock Down 3.8%

NASDAQ:VTYX traded down $0.15 during mid-day trading on Wednesday, hitting $3.83. 1,391,936 shares of the company traded hands, compared to its average volume of 1,316,851. The stock's fifty day moving average price is $2.73 and its 200-day moving average price is $2.14. Ventyx Biosciences has a one year low of $0.78 and a one year high of $4.05. The firm has a market cap of $273.12 million, a price-to-earnings ratio of -2.28 and a beta of 1.01.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.07. Equities analysts predict that Ventyx Biosciences will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Ventyx Biosciences

A number of hedge funds have recently made changes to their positions in the company. Hudson Bay Capital Management LP purchased a new stake in shares of Ventyx Biosciences in the second quarter worth about $34,000. Tower Research Capital LLC TRC lifted its position in shares of Ventyx Biosciences by 337.1% in the second quarter. Tower Research Capital LLC TRC now owns 36,834 shares of the company's stock worth $79,000 after buying an additional 28,407 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Ventyx Biosciences during the second quarter worth approximately $42,000. Brevan Howard Capital Management LP bought a new stake in Ventyx Biosciences during the second quarter worth approximately $246,000. Finally, Ameriprise Financial Inc. bought a new stake in Ventyx Biosciences during the second quarter worth approximately $60,000. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.